NGS-Based RNA-Sequencing Market by Product & Services, Technology, Application, End-User

List of Tables

The NGS-Based RNA-Sequencing Market was valued at USD 2.32 billion in 2023, expected to reach USD 2.67 billion in 2024, and is projected to grow at a CAGR of 17.32%, to USD 7.12 billion by 2030.

NGS-Based RNA-Sequencing, which enables comprehensive analysis of the transcriptome, promises to revolutionize genomics research by providing detailed insights into gene expression, discovery of novel transcripts, and enhanced understanding of gene regulation mechanisms. The necessity of RNA-Sequencing arises from its ability to deliver precise, accurate, and high-throughput data essential for advancing personalized medicine, identifying new therapeutic targets, and understanding complex biological systems. Applications span from oncology to neurology, playing a crucial role in disease research, diagnostics, and drug discovery. End-use markets encompass academic and research institutes, clinical diagnostics labs, pharmaceutical and biotech companies, underscoring broad application versatility. Market growth is underpinned by factors such as increasing preference for personalized medicine, growing funding for genomic research, and technological advancements in sequencing technology that drive down costs and improve accessibility. Latest opportunities include integrating AI and machine learning for data analysis, enhancing the application of RNA-Sequencing in non-model organisms and less-studied diseases, and expanding its utility in biomarker discovery and precision medicine. Companies should focus on collaborations with research institutions to drive innovation and explore unique sequencing applications. However, limitations like high initial costs, data complexity, and the requisite for sophisticated infrastructure challenge market expansion. Regulatory complexities and ethical concerns related to genetic data further complicate the landscape. Innovation opportunities lie in advancing sequencing technologies to offer faster and more cost-efficient solutions, developing robust data analysis tools to streamline interpretations, and focusing on user-friendly platforms to democratize access. As the market matures, leveraging cloud computing for data storage and computation will be vital, and strategic industry-academic collaborations will be central to exploring nascent opportunities. The RNA-Sequencing market is dynamic and rapidly evolving, marked by robust growth potential as it aligns increasingly with healthcare innovation and research frontiers.

KEY MARKET STATISTICS
Base Year [2023]	USD 2.32 billion
Estimated Year [2024]	USD 2.67 billion
Forecast Year [2030]	USD 7.12 billion
CAGR (%)	17.32%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving NGS-Based RNA-Sequencing Market

The NGS-Based RNA-Sequencing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Surge in the adoption of next-generation sequencing
- Robust growth of precision medicines and rising amount of RNA sequencing grants
- Increasing demand for advanced sequencing-based diagnostics
Market Restraints
- Cost of NGS instruments is high
Market Opportunities
- Technological advancement in the RNA-Sequencing
- Increasing research activities related to RNA-Sequencing
Market Challenges
- Unavailability of skilled manpower

Porter's Five Forces: A Strategic Tool for Navigating the NGS-Based RNA-Sequencing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the NGS-Based RNA-Sequencing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the NGS-Based RNA-Sequencing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the NGS-Based RNA-Sequencing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the NGS-Based RNA-Sequencing Market

A detailed market share analysis in the NGS-Based RNA-Sequencing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the NGS-Based RNA-Sequencing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the NGS-Based RNA-Sequencing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the NGS-Based RNA-Sequencing Market

A strategic analysis of the NGS-Based RNA-Sequencing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the NGS-Based RNA-Sequencing Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Becton, Dickinson and Company, BGI Group, Eurofins Scientific, F. Hoffmann-la Roche AG, Genewiz by Brooks Automation, Inc., Hamilton Company, Illumina, Inc., Merck KGaA, Oxford Nanopore Technologies, PerkinElmer, Inc., Psomagen, Qiagen N.V., Takara Bio Inc., and Thermo Fisher Scientific.

Market Segmentation & Coverage

This research report categorizes the NGS-Based RNA-Sequencing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product & Services, market is studied across Data Analysis, RNA Sequencing Platforms & Consumables, RNA Sequencing Services, Sample Preparation Products, and Storage & Management.
Based on Technology, market is studied across Ion Semiconductor Sequencing, Nanopore Sequencing, Sequencing By Synthesis, and Single-Molecule Real-Time Sequencing.
Based on Application, market is studied across De Novo Transcriptome Assembly, Expression Profiling Analysis, Small RNA Sequencing, and Variant Calling & Transcriptome Epigenetics.
Based on End-User, market is studied across Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Research & Academia.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-2214614769D5

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Surge in the adoption of next-generation sequencing
  - 5.1.1.2. Robust growth of precision medicines and rising amount of RNA sequencing grants
  - 5.1.1.3. Increasing demand for advanced sequencing-based diagnostics
- 5.1.2. Restraints
  - 5.1.2.1. Cost of NGS instruments is high
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancement in the RNA-Sequencing
  - 5.1.3.2. Increasing research activities related to RNA-Sequencing
- 5.1.4. Challenges
  - 5.1.4.1. Unavailability of skilled manpower
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. NGS-Based RNA-Sequencing Market, by Product & Services

6.1. Introduction
6.2. Data Analysis
6.3. RNA Sequencing Platforms & Consumables
6.4. RNA Sequencing Services
6.5. Sample Preparation Products
6.6. Storage & Management

7. NGS-Based RNA-Sequencing Market, by Technology

7.1. Introduction
7.2. Ion Semiconductor Sequencing
7.3. Nanopore Sequencing
7.4. Sequencing By Synthesis
7.5. Single-Molecule Real-Time Sequencing

8. NGS-Based RNA-Sequencing Market, by Application

8.1. Introduction
8.2. De Novo Transcriptome Assembly
8.3. Expression Profiling Analysis
8.4. Small RNA Sequencing
8.5. Variant Calling & Transcriptome Epigenetics

9. NGS-Based RNA-Sequencing Market, by End-User

9.1. Introduction
9.2. Hospitals & Clinics
9.3. Pharmaceutical & Biotechnology Companies
9.4. Research & Academia

10. Americas NGS-Based RNA-Sequencing Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific NGS-Based RNA-Sequencing Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa NGS-Based RNA-Sequencing Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Agilent Technologies
2. Becton, Dickinson and Company
3. BGI Group
4. Eurofins Scientific
5. F. Hoffmann-la Roche AG
6. Genewiz by Brooks Automation, Inc.
7. Hamilton Company
8. Illumina, Inc.
9. Merck KGaA
10. Oxford Nanopore Technologies
11. PerkinElmer, Inc.
12. Psomagen
13. Qiagen N.V.
14. Takara Bio Inc.
15. Thermo Fisher Scientific